ERRATUM
Erratum in «High rate of virologic supression with darunavir/ritonavir plus optimazed background therapy among highly antiretroviral-experienced HIV-infected patients: results of a prospective cohort study in São Paulo, Brazil»
José Ernesto VidalI,II,* * Corresponding author: Department of Infectious Diseases, Instituto de Infectologia Emílio Ribas, Avenida Doutor Arnaldo, Cerqueira, César, São Paulo, SP, 01246-000, Brazil. Tel.: +55 11 38961200; fax: +55 11 38961200. E-mail address: josevibe@gmail.com (J. Ernesto Vidal). ; Alice Tung Wan SongI; Maria Laura MatosI; Daniel BartmannI; Guilherme dos AnjosI; Érique José Peixoto de MirandaI; Ângela Carvalho FreitasI; Mirian de Freitas DalbenI; Claudinei SantanaIII; Aluísio Cotrim SeguradoI; Cláudia Cortese BarretoIV,V; Adrián Vladimir HernándezVI
IDepartment of Infectious Diseases, Medical School, Universidade de São Paulo, São Paulo, SP, Brazil
IIDepartment of Infectious Diseases, Instituto de Infectologia Emílio Ribas, São Paulo, SP, Brazil
IIIPharmacy School, Universidade de São Paulo, São Paulo, SP, Brazil
IVPro-Blood Foundation/Blood Center of São Paulo (FPS/HSP), Medical School, Universidade de São Paulo, São Paulo, SP, Brazil
VLaboratory of Medical Investigation in Dermatology and Immunodeficiencies - LIM-56, Department of Dermatology, Medical School, Universidade de São Paulo, São Paulo, SP, Brazil
VIDepartment of Quantitative Health Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, USA
In the article "High rate of virologic supression with darunavir/ritonavir plus optimazed background therapy among highly antiretroviral-experienced HIV-infected patients: results of a prospective cohort study in São Paulo, Brazil", published in Braz J Infect Dis. 2013 Feb;17(1):41-7, please consider the following corrections:
Page 43, Table 1, line 18, "Previous use of NRTI, NNRTI and PIs: 87 (95)" should read as "Previous use of NRTI, NNRTI and PIs: 92 (100%)".
Page 43, Results section, lines 28-31, "Tenofovir was the most frequent NRTI used (n = 83, 90.2%) and its genotyping evaluation were: sensitive: 16 (17.4%), intermediate resistance: 8 (8.7%), and resistance: 68 (73.9%)." should read as "All patients received lamivudine and their genotyping evaluation were resistant in all cases. Tenofovir was the second most frequent NRTI used (n = 83, 90.2%) and its genotyping evaluation were: sensitive:14 (16.9%), intermediate resistance: 7 (8.4%), and resistance: 62 (74.7%)."
Publication Dates
-
Publication in this collection
13 June 2013 -
Date of issue
June 2013
